Background

Fetuin-A, a liver-derived glycoprotein that impairs insulin-signalling, has emerged as a biomarker for diabetes risk. Although moderate alcohol consumption has been inversely associated with fetuin-A, data from clinical trials are lacking. Thus, we evaluated whether moderate alcohol consumption decreases circulating levels of fetuin-A.

Results

Circulating fetuin-A concentrations decreased in men after vodka consumption (Mean ± SEM: 441 ± 11 to 426 ± 11 μg/ml, p = 0.02), but not in women after wine (448 ± 17 to 437 ± 17 μg/ml, p = 0.16) or beer consumption (498 ± 15 to 492 ± 15 μg/ml, p = 0.48) compared to levels after each corresponding alcohol-free treatment. Post-hoc power analyses indicated that the statistical power to detect a similar effect as observed in men was 30% among the postmenopausal women and 31% among the premenopausal women.

Conclusions

In these randomized crossover trials, moderate alcohol consumption decreased fetuin-A in men but not in women. This sex-specific effect may be explained by the relatively short intervention periods or the low statistical power in the trials among women.

Trials registration

Fetuin-A (α-Heremans-Schmid glycoprotein) is an abundant hepatokine that impairs insulin signalling by inhibiting tyrosine kinase activity [1, 2]. Several prospective studies have reported positive associations between circulating fetuin-A and type 2 diabetes risk and, concomitantly, observed inverse relations between alcohol consumption and fetuin-A [3–5]. More importantly, a recent case-control study suggested that fetuin-A may partially explain the reduced risk of type 2 diabetes [6] that has consistently been observed with moderate alcohol consumption [7–9]. However, the cross-sectional and observational nature of these alcohol-fetuin-A associations may raise concern about potential confounding. Thus, to comprehensively investigate the effect of moderate alcohol consumption on fetuin-A levels, we performed post-hoc analyses of three randomized crossover interventions with different alcohol-containing beverages in men and women.

The rationale of the three trials was to study the effect of moderate alcohol consumption on markers of insulin sensitivity and/or inflammation. Each trial is registered at ClinicalTrials.gov: NCT00285909, NCT00524550, and NCT00918918. Independent medical ethics committees approved the research protocols (The Medical Ethics Committee of the University Medical Centre Utrecht; Utrecht, the Netherlands [NCT00285909] and METOPP; Tilburg, the Netherlands [NCT00524550, and NCT00918918]) and all participants gave written informed consent. Eligible subjects were apparently healthy, were habitual alcohol consumers, refrained from smoking, and had no family history of alcoholism. The design of each individual intervention has been described in more detail elsewhere [10–12]. In short, the three studies were open-label, randomized, crossover intervention trials and were all conducted at TNO (a Dutch acronym for Netherlands Organisation of Applied Scientific Research) in Zeist, the Netherlands. The trials consisted of 1) 36 postmenopausal women consuming 250 ml white wine (25 g alcohol; Chardonnay; Jean d’Alibert, Rieux, France) or white grape juice (Albert Heijn, Zaandam, the Netherlands) daily for 6 weeks between March and June 2006, 2) 24 premenopausal women consuming 660 ml beer (26 g alcohol) or alcohol-free beer daily (both Amstel, Amsterdam, the Netherlands) for 3 weeks between August and November 2007, and 3) 24 young men consuming 100 ml vodka (30 g alcohol; Smirnoff, Diageo, London, UK) and 200 ml orange juice (Appelsientje, Riedel, Ede, The Netherlands) or only orange juice daily for 4 weeks between August and November 2009. Postmenopausal women had an absence of menses for at least two years. Premenopausal women used phase I or II oral contraceptives. Allocation to treatment order (alcohol-containing vs. alcohol-free period) was randomized according to age and body mass index (BMI). After each treatment period, fasting blood samples were obtained. Plasma samples were stored at −80°C (beer and vodka trials) and serum samples at −20°C (wine trial) until analysis. Fetuin-A concentrations were determined by a sandwich enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) with a mean intra-assay coefficient of variation of 6.8%.

Data were analyzed using SAS statistical software (version 8.2; SAS Institute, Cary, NC, USA). Variables were compared between treatments with a mixed analysis of variation (ANOVA) model that included terms for treatment, period and the interaction between period and treatment (indicating possible carryover effects). Correlation coefficients were computed according to Spearman rank order to assess associations between intervention-induced changes in fetuin-A and other biochemical variables. Data are presented as mean ± standard error of the mean (SEM). All tests were two-sided. Statistical significance was defined as p < 0.05.

All subjects completed both arms of their intervention. No notable adverse effects were reported. Age and BMI were 56.5 ± 4.2 y and 25.4 ± 3.3 kg/m2 in postmenopausal women, 23.9 ± 4.3 y and 22.2 ± 1.6 kg/m2 in the premenopausal women, and 25.5 ± 4.3 y and 22.2 ± 1.6 kg/m2 in the men, respectively. Indicators of compliance were the increased high-density lipoprotein (HDL)-cholesterol and adiponectin levels after each of the three alcohol consumption periods compared with after the alcohol-free consumption periods (Table 1).

No carry-over effects were found in fetuin-A, indicating that a possible effect on fetuin-A levels due to a treatment given in the first time period of the crossover trial did not persist into the second period and influence the effect of the second treatment. Fetuin-A levels decreased in men after vodka juice consumption (441 ± 11 to 426 ± 11 μg/ml, p = 0.02) but not significantly in postmenopausal women after wine (448 ± 17 to 437 ± 17 μg/ml, p = 0.16) or in premenopausal women after beer consumption (498 ± 15 to 492 ± 15 μg/ml, p = 0.48) (Figure 1) as compared to levels after each corresponding alcohol-free beverage consumption.

Figure 1

Individual changes of circulating fetuin-A levels at the end of the alcohol or alcohol-free treatment periods after an overnight fast for three open-label randomized crossover trials.

In post-hoc analyses of three separate open-label randomized crossover intervention studies, we found that moderate alcohol consumption reduced fetuin-A levels in men but not in women. This decrease was apparent after four weeks of moderate vodka consumption. No consistent correlations between intervention-induced changes in fetuin-A and other biochemical markers were observed across the three studies.

To our knowledge, these are the first intervention studies investigating the effect of different alcohol-containing beverages on circulating fetuin-A. The lowered fetuin-A levels in men after moderate alcohol consumption partially confirm cross-sectional observations in several epidemiological studies [3–6, 13, 14] and may provide some physiological support for the protective effect of moderate alcohol consumption on the risk of developing type 2 diabetes [6, 8] besides adiponectin [15]. Furthermore, these findings extend prior evidence of short-term clinical trials that noted favourable changes in selected biological markers associated with diabetes and cardiovascular risk after moderate alcohol consumption [16].

The underlying physiological explanation how alcohol consumption may lower fetuin-A is not clear. Also, the sex-specific alcohol-fetuin-A effect was unexpected, particularly since all women were either on oral contraceptives or postmenopausal, which limits potential influences of hormonal fluctuations or menstrual cycles. The null finding in our trials among pre- and postmenopausal women do not seem to correspond with a previous observational study among 1331 middle-aged and older US female nurses, where moderate alcohol consumption was inversely associated with plasma fetuin-A even after adjustment for several lifestyle variables, demographic information, and medical history [6]. Perhaps this discrepancy can be explained by the low statistical power in the two trials among women. Post-hoc power analyses indicated that the power to detect a similar effect as observed in men was only 30% among the postmenopausal women and 31% among the premenopausal women.

Circulating fetuin-A was strongly and negatively associated with the insulin-sensitizing adipokine adiponectin in humans [17] and treatment of human adipocytes with fetuin-A repressed ADIPOQ mRNA levels [17]. Furthermore, given the prior associations between fetuin-A and insulin resistance [18] and insulin sensitivity [19], we hypothesized that reductions in fetuin-A may play a role in the increased adiponectin levels or improved insulin sensitivity after alcohol consumption [10]. Therefore, we analyzed correlations between intervention-induced changes in fetuin-A and adiponectin levels and other markers of insulin sensitivity, such as HOMA-IR. We, however, did not find such inverse correlations despite the fact that moderate alcohol consumption increased both ADIPOQ expression [10] and corresponding circulating adiponectin levels [10–12], suggesting that fetuin-A and adiponectin levels may be independently affected by alcohol. Also, it is important to note that the HOMA-IR index is a weak estimate of insulin resistance, particularly in a small study. The absence of a correlation between alcohol-induced changes in fetuin-A and HOMA-IR may partially be explained by the relatively low FFA levels of the studied participants. In a study among 347 healthy subjects at increased risk of type 2 diabetes, fetuin-A was only inversely associated with insulin sensitivity among individuals with high FFA levels (~ > 0.65 mmol/l) [20].

Strengths of the study are the randomized crossover design (considered the ‘gold standard’ for evidence-based research), the assessment of compliance markers (i.e. HDL-cholesterol and adiponectin) to the study treatments, the inclusion of both sexes, and the broad range of biochemical variables. Some limitations warrant consideration. The trials consisted of alcohol-administration periods of 3 to 6 weeks and were performed among fairly insulin-sensitive subjects. Maybe more profound effects on fetuin-A levels would have been observed if the interventions lasted longer and/or were executed in subjects with glucose levels in the (pre)diabetic range. For example, three months of moderate alcohol consumption decreased fasting glucose levels among subjects with impaired glucose metabolism [21] and fetuin-A levels were particularly associated with an increased diabetes risk among subjects with higher fasting glucose [3, 5]. Regardless, the duration of the present interventions were long enough to detect alcohol-induced changes in other biochemical markers such as adiponectin and HDL-cholesterol. Also, the association between moderate alcohol consumption and lower risk of type 2 diabetes mellitus is not limited to subjects with impaired glucose metabolism but also exists for subjects already at low risk for diabetes on the basis of multiple combined low-risk lifestyle behaviours [22]. Nevertheless, the subjects studied were rather lean (mean BMI values 22-26), had no fatty liver (low liver enzyme levels) and were rather insulin sensitive (low HOMA-IR). Also, all premenopausal women used oestrogen-containing oral contraceptives, which may explain their somewhat higher fetuin-A levels given the positive associations between oestrogen and fetuin-A [23, 24]. Thus, the data are not representative for a typical at-risk population for metabolic diseases. Second, the daily amounts of alcohol consumed by women (~25 g alcohol) were higher than what is considered ‘moderate’ according to most guidelines (i.e. max. ~15 g alcohol). However, the nadir of the alcohol-diabetes association for women appeared to be at 24 g of alcohol/day in a meta-analysis of 20 prospective studies [8] while alcohol consumption became harmful above 50 g/day (and above 60 g/day for men). Third, post-hoc power analyses showed that there was low statistical power in the two trials among women to detect a similar effect as observed in the trial among men. Fourth, although unlikely since vodka is basically an ethanol-water mixture, we cannot fully exclude a potential beverage-specific effect. Finally, the alcohol-induced reductions in fetuin-A were comparable to associations reported in epidemiological studies [3, 5, 6], but were relatively small as compared to alcohol’s effect on HDL-cholesterol and adiponectin. It is possible that the findings, including the sex differences, were due to chance.

In conclusion, the results of these three randomized clinical trials with different alcohol-containing beverages demonstrated that short-term moderate alcohol consumption decreases fetuin-A levels in men but not in women. Further research is needed to determine whether long-term moderate alcohol consumption decreases fetuin-A levels. If so, these findings may add to the current knowledge of possible metabolic benefits of moderate alcohol consumption.

Acknowledgements

This work was supported by the Dutch Ministry of Economic Affairs, Agriculture and Innovation and by the Dutch Foundation for Alcohol Research (SAR) representing Dutch producers of and traders in beer, wine and spirits and by TNO. Their joint aim is to independently study the health effects of moderate alcohol consumption.

Authors' original submitted files for images

Below are the links to the authors’ original submitted files for images.

Competing interests

The authors have no potential conflicts relevant to this article.

Authors’ contributions

MMJ conceived the idea of the study, designed the study, directed the study’s implementation, conducted the statistical analyses, interpreted the data, and wrote the manuscript. ICS assisted in the study’s implementation, assisted in the interpretation of the data, and critically edited the manuscript. HFJH designed the study, directed the study’s implementation, assisted in the interpretation of the data, critically edited the manuscript, and obtained funding. All authors read and approved the final manuscript.

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.